Search filters

Filters
Clear All

Phase

  • 8
  • 10
  • 3
  • 2
  • 24
  • 13
  • 24

Found 24 Small Cell Lung Cancer trials

A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 UPCC 15518 / ANAM-17-21: A Phase 3  Randomized  Double-Blind  Placebo-Controlled  Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 3
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
99 years or below
All genders
Phase 1
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
99 years or below
All genders
The basic premise of this pilot study is to enroll 40 patients over 1.5 years who have Stage III or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation when a contrast-enhanced 4DCT is planned. The primary goal is to quantify the reproducibility of lung …
 Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
18 years - 99 years
All genders
Phase 2
Interventional
The main purpose of this study is to measure when the effectiveness of durvalumab in combination with other experimental drugs is superior to the effectiveness of durvalumab when used alone. The study is also being done to evaluate the safety and tolerability of durvalumab when used alone and in combination …
 S1900B A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
18 years - 99 years
All genders
Phase 2
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
 UPCC 16517: A Phase 1  First-in-Human  Open-Label  Dose Escalation Study of JNJ-61186372  a Human Bispecific EGFR and cMet Antibody  in Subjects with Advanced Non-Small Cell Lung Cancer
99 years or below
All genders
Phase 1
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
 An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib)  a Third Generation EGFR-TKI  as Monotherapy or in Combinations With JNJ-61186372  a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
18 years - 99 years
All genders
Phase 1
the purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC). Eligible subjects will be those with NSCLC.
99 years or below
All genders
Phase 2
The primary purpose of this study is to gain information about the safety and activity of grapiprant when taken with pembrolizumab in patients who have actively growing or spreading type of advanced stage lung cancer called non-small cell lung cancer (NSCLC).
 Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors
18 years - 99 years
All genders
Phase 1
Interventional
study of surufatinib in combination with tislelizumab will evaluate the safety, and tolerability in patients with advanced solid tumors.
11 - 20 of 24